- A fundraising led and conducted by the American investment company Viscogliosi Brothers, LLC, specialized in the financing of disruptive therapeutic innovations in spine, orthopedics, and healthcare with the co-investment of a leading global medical technology company.
- This fundraising will be used to accelerate the strategic development of Companion Spine, the world’s first pure player specialized in back pain treatment exclusively through spinal joint functional motion preservation, early diagnostic and interventional surgery solutions for the treatment of degenerative disc disease and lumbar spinal stenosis; two of the world’s most common spinal conditions, with more than 10 million potential cases every year in the United States alone.
Understanding the innovation developed by Companion Spine
Companion Spine is the first company in the world to develop a portfolio of non-invasive diagnostic and medical implant solutions for the treatment of degenerative disc disease and lumbar spinal stenosis.
Companion Spine’s solutions allow for immediate and precise identification of the disease state and root causes, and provide patients with appropriate solutions to treat the pain while preserving full mobility of the spine, respecting and preserving anatomy.
Companion Spine offers patients and spine pain specialists (both pain management physicians and spine surgeons) effective, clinically validated, light, reversible, interventional, and non-invasive alternatives, perfectly adapted to an application in ambulatory surgery while preserving treatments options open for both patient and physician.
Companion Spine’s approach includes a set of solutions applicable very early in the development of each pathology, thus constituting an earlier stage treatment alternative to spinal fusion, the current standard surgical solution for treating the most disabling back pain.
Companion Spine LLC, the France-USA specialist in diagnostic and interventional spine surgery, announced that it has raised $55 million. This Series A financing was led by Viscogliosi Brothers, the company’s co-founder and historical shareholder, and jointly invested by a leading global medical technology company.
Viscogliosi Brothers initiated and formed Companion Spine to focus on spine pain treatment, motion preservation, precision diagnostics and interventional care to allow for a comprehensive spine health and a total spine care continuum approach for patients, spine pain specialists, treatment centers and payors.
The funds raised will be used primarily for the development and commercialization of Companion Spine’s range of minimally invasive diagnostic and therapeutic solutions in the United States and internationally for the treatment of the two main indications targeted by the company: Degenerative Disc Disease (DDD) and Lumbar Spine Stenosis (LSS), two of the most common spine diseases in the world,with more than 10 million potential cases identified in the United States alone including several million patients suffering from severe back pain without an effective therapeutic solution.
Companion Spine’s medical and diagnostic solutions, stemming in part from the acquisition from Medtronic in September 2020 of regulatory and clinical property, including a portfolio of six patent families covering a total of more than 140 patents, as well as an inventory of instruments and implants sets, specifically address this population of patients whose medical needs are currently not properly diagnosed and are therefore poorly managed, sometimes allowing pain to last and worsen for years without any specific intervention.
In order to complete its unique offer to patients, to pain management physicians and to spine surgeons, Companion Spine additionally intends to finalize the development of innovative diagnostic tools allowing very early diagnostic with unprecedented precision of the root causes and the biomechanical and biological factors that precisely induce pain, including their stage of advancement that may impact the functionality of the spine. These diagnostic techniques are intended to allow for improved diagnosis and prediction by a simple and mini-invasive approach, contributing to the choice of the final therapeutic solution and its success.
Companion Spine’s unique positioning, combining early spine pathologies diagnosis with effective, non-invasive, reversible medical solutions and interventional surgery, paves the way for a new way of managing spine pain, allowing patients to avoid heavier and irreversible treatment options such as spine fusion.
Two of Companion Spine’s products are expected to be commercialized in the U.S. in 2023: The DIAMTM implant for the treatment of degenerative disc disease, is already CE marked. It has received the Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) in October 2021, a designation granted to devices capable of providing a therapeutic answer to a group of patients for which no therapeutic solution exists, thus ensuring its accelerated development; and the APERIUSTM intervertebral implant for the percutaneous treatment of Lumbar Stenosis.
“We are witnessing a paradigm shift in the management of spine pathologies, as many other healthcare sectors have experienced with the development of new technical and scientific innovations. Companion Spine is positioned to become a major actor of this change due to its unique focus and its comprehensive solutions which are adapted to the needs of patients and back pain specialists throughout their entire journey, aiming at precisely diagnosing and treating back pain earlier, for good, precisely, and efficiently. Patients and health authorities are now in favor of these quicker, lighter, less risky and highly effective interventional surgical techniques and their ability to compete with, and even surpass, the standard of irreversible treatment imposed by spinal fusion,” said Erick Cloix, CEO and co-founder of Companion Spine. “I am thrilled by the completion of this very important financing in our sector of activity, which testifies not only to the support and confidence of our co-founder and main shareholder, Viscogliosi Brothers, but also to the medical relevance of the technologies for the preservation and protection of functional mobility of the spinal segment, and to the interest of the business model developed by Companion Spine, with the participation of a leading spine medical devices manufacturer from which a large part of the patents for some of our innovations originate. With this fundraising, which provides us with a solid cash flow and long-term financial visibility, Companion Spine will be able to focus entirely on the development and commercialization of its first group of medical, diagnostic, and implantable devices, specifically DIAMTM and APERIUSTM, our spinal implants for the treatment of low back pain, as well as DISC ANALYZERTM, a new and unique technology for the precise diagnosis and monitoring of back pain. United-States commercialization of these breakthrough innovations is expected during 2023 and 2024.”
“I am excited to embrace this opportunity to serve the American patients and the Spine Pain Management community with technologies such as DIAMTM that have a uniquely long and strong successful clinical history outside the United States since 2003 as well as APERIUSTM, said Anthony G. Viscogliosi, Principal at Viscogliosi Brothers, Co-founder and Executive Chairman of Companion Spine. “The breakthrough status awarded to the DIAMTM technology by the FDA in October of last year recognizes the unique characteristics of this technology to address currently unmet patient care needs here in the USA.
I am delighted to work with such a talented and experienced management team that has gathered around the vision and mission of Companion Spine. I believe this group is uniquely experienced to achieve great success within the field of diagnostics and interventional spine pain treatment, as well as motion preservation and function. The trust and support from one of the leading global spine medical device company in the participation in current and future developments for Companion Spine alongside Viscogliosi Brothers provide us with the confidence that Companion Spine’s vision and mission are rightfully aimed at what spine pain specialists and patients deserve and have long awaited for.”
Companion Spine already has its own subsidiary in the United States to market its medical devices and future diagnostic solutions. Companion Spine is currently in discussions with several companies in the industry with the objective of establishing potential partnerships and acquisitions of complementary products and technologies that could strengthen its portfolio of innovative diagnostic and medical solutions.
About Companion Spine:
Founded in 2020 in New-York, United States, and Bordeaux, France, Companion Spine is a company specialized in the diagnosis and interventional and surgical treatment of spine conditions. Companion Spine’s comprehensive technologies and solutions target degenerative disc disease and lumbar spinal stenosis, two of the most common indications for back pain worldwide. Companion Spine is developing a portfolio of medical solutions that will allow back pain specialists to offer their patients earlier, effective and reversible alternatives to spinal fusion, the current standard surgical approach and strategy to address the most severe back pain.
For more information, please visit: www.companion-spine.com
About Viscogliosi Bros., LLC
Viscogliosi Brothers LLC (VB) was established by Marc R. Viscogliosi, John J. Viscogliosi and Anthony G. Viscogliosi in 1999 as the first venture capital/private equity and merchant banking firm dedicated to the neuromusculoskeletal/orthopedics sector of the healthcare industry. VB is headquartered in NYC. Today, VB is an independent firm with a mission to create, build and finance companies founded on innovations that are uniquely focused on life changing neuromusculoskeletal/orthopedic technologies globally. VB has founded, invested in, and built more than 35 companies in the sector. VB specializes in merchant banking activities in the neuromusculoskeletal industry as a full life cycle investor, investing in all stages of a company from inception through growth capital and IPO or sale to a strategic buyer, all the while helping hundreds of thousands of people lead better lives through the orthopedic and spinal innovations developed, marketed and sold by the companies VB has assisted in financing. VB has effected 18 exits over its 23 years generating more than $2.5 billion in capital returned to its lenders, partners, and itself.
For more information, please visit: www.vbllc.com
